<span item_type="fundamental" item_id="2a0068c9b8ebc34d20c43edb517c9f8c" counter_id="ST/US/IMA" env="prod"></span><span item_type="announcement" item_id="581940971229221121" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD -2.91.</p><p></p><h4>Cash Position</h4><p>As of September 30, 2025, ImageneBio, Inc. had cash, cash equivalents, and marketable securities totaling $142.6 million, a significant increase from $12.1 million as of December 31, 2024. This increase was primarily due to the merger between Inmagene Biopharmaceutics and Ikena Oncology, Inc., along with a $75.0 million private placement.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1835579/000119312525275910/d61077dex991.htm"></span></p><h4>Research and Development (R&amp;D) Expenses</h4><p>R&amp;D expenses for the three months ended September 30, 2025, were $15.6 million, compared to $3.9 million for the same period in 2024. The $11.7 million increase was mainly due to higher clinical trial expenses and non-cash stock-based compensation expenses following the merger.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1835579/000119312525275910/d61077dex991.htm"></span></p><h4>General and Administrative (G&amp;A) Expenses</h4><p>G&amp;A expenses for the three months ended September 30, 2025, were $11.0 million, up from $1.7 million for the same period in 2024. The $9.3 million increase was primarily attributed to a $5.2 million rise in stock-based compensation and increased professional services and compensation costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1835579/000119312525275910/d61077dex991.htm"></span></p><h4>Net Loss</h4><p>The net loss for the three months ended September 30, 2025, was $24.8 million, compared to $3.2 million for the same period in 2024. The $21.6 million increase was due to additional operating costs related to the merger and associated transaction costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1835579/000119312525275910/d61077dex991.htm"></span></p><h4>Outlook / Guidance</h4><p>ImageneBio plans to submit a protocol amendment for the ongoing Phase 2b ADAPTIVE study to expand dosing regimens and optimize study design, aiming to demonstrate the differentiated potential of IMG-007. Topline data from the study is expected in 2027.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1835579/000119312525275910/d61077dex991.htm"></span></p>

ImageneBio | 8-K: FY2025 Q3 Revenue: USD 0